Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Immune dysregulation and clonal hematopoiesis in MDS

Toshio Kitamura • 21 Oct 2022
ESH CML 2022
Myelodysplastic Syndromes

Toshio Kitamura, MD, PhD, The University of Tokyo, Tokyo, Japan, comments on immune dysregulation and clonal hematopoiesis (CH) in myelodysplastic syndromes (MDS), discussing the impact epigenetic mutations in hematopoietic stem cells (HSCs) can have on T cells and tumor immunity. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisor for Rigel

More from Toshio Kitamura

1:07
The impact of BCR-ABL mutations on signaling pathway activation in CML
Toshio Kitamura • 21 Oct 2022
2:24
Rationale for targeting leukemic stem cells with PDL1 antibodies or IRAK inhibitors
Toshio Kitamura • 21 Oct 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals